Small-cell carcinoma of the lung: the prognostic significance of stage on survival

Judith A. Cooksey, Jacob D. Bitran, Richard K. Desser, Ann E. Kinnealey, Uri Mintz, Martin Colman, George Cimochowski, Melvin L. Griem, Tom R. Demeester, Harvey M. Golomb

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Thirty-three patients (pts) with small cell carcinoma (SCC) were treated with combined modality therapy consisting of radiation therapy (300 rad/15 fractions) and cyclophosphamide, adriamycin, methotrexate and leucovorin (CAML). Thirty of 33 pts showed an objective response to therapy with a median survival of 11.6 months for all patients. When survival was determined by stage, pts with disease limited to the chest had a better median survival (18.9 months) than pts with metastases to supraclavicular nodes (11.6 months, median) or wide-spread metastatic disease (8.0 months, median). Not withstanding the routine use of chest irradiation, lung recurrences developed in 7/33 pts and were more frequent than CNS relapse, 4/33. If survival is to be increased in SCC, more aggressive means of local tumor control need to be pursued.

Original languageEnglish (US)
Pages (from-to)859-865
Number of pages7
JournalEuropean Journal of Cancer (1965)
Issue number6
StatePublished - Jun 1979

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Small-cell carcinoma of the lung: the prognostic significance of stage on survival'. Together they form a unique fingerprint.

Cite this